Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Dicerna Pharmaceuticals' : New Drug Application Targeting Alcohol Use Disorder Gets FDA Clearance; Plans Phase 1 Trial in Q3

07/29/2021 | 03:14pm EDT


ę MT Newswires 2021
All news about DICERNA PHARMACEUTICALS, INC.
09/21INSIDER SELL : Dicerna Pharmaceuticals
MT
09/07DICERNA PHARMACEUTICALS : Corporate Overview
PU
09/02DICERNA PHARMACEUTICALS : to Participate in 16th Annual Citi Biopharma Conference
BU
08/12DICERNA PHARMACEUTICALS : Corporate Overview
PU
08/12NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
08/11DICERNA PHARMACEUTICALS : B. Riley Lowers Dicerna Pharmaceuticals' PT to $35 from $49 on H..
MT
08/11DICERNA PHARMACEUTICALS : Goldman Sachs Cuts Dicerna Pharmaceuticals to Neutral From Buy, ..
MT
08/10INSIDER TRENDS : Insider Buying Continued with Purchase of Dicerna Pharmaceuticals Stock
MT
08/10DICERNA PHARMACEUTICALS : Chardan Capital Adjusts Price Target on Dicerna Pharmaceuticals ..
MT
08/10DICERNA PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Dicerna Pharmaceuticals to..
MT
More news
Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 179 M - -
Net income 2021 -144 M - -
Net cash 2021 501 M - -
P/E ratio 2021 -11,0x
Yield 2021 -
Capitalization 1 608 M 1 608 M -
EV / Sales 2021 6,20x
EV / Sales 2022 6,26x
Nbr of Employees 302
Free-Float 91,8%
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DICERNA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 20,68 $
Average target price 30,89 $
Spread / Average Target 49,4%
EPS Revisions
Managers and Directors
Douglas M. Fambrough President, Chief Executive Officer & Director
Douglas W. Pagßn Chief Financial Officer
J. Kevin Buchi Chairman
Bob D. Brown Chief Scientific Officer
Shreeram Aradhye Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
DICERNA PHARMACEUTICALS, INC.-6.13%1 608
GILEAD SCIENCES, INC.23.12%89 936
BIONTECH SE318.73%82 443
WUXI APPTEC CO., LTD.35.75%69 407
REGENERON PHARMACEUTICALS33.91%67 262
VERTEX PHARMACEUTICALS-21.38%48 202